TGF-β pathway as a therapeutic target in bone metastases

Patricia Juárez, Theresa A. Guise

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Breast and prostate cancer frequently metastasizes to the skeleton and causes bone destruction. In skeletal tissue, transforming growth factor-β (TGF-β ) is a major bone-derived factor responsible for driving a feed-forward vicious cycle of breast cancer growth in bone. TGF-β is released from bone in active form by osteoclastic resorption and increases the tumor secretion of factors, which stimulate osteolytic destruction of the bone adjacent to the tumor. Moreover it activates epithelial-mesenchymal transition and tumor cell invasion, increases angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor and bone offers a target for therapeutic intervention to decrease skeletal metastasis. Here we summarize the current knowledge of TGF-β in bone metastases, the use of TGF-β inhibitors and its potential for clinical use and consequences.

Original languageEnglish (US)
Pages (from-to)1301-1312
Number of pages12
JournalCurrent Pharmaceutical Design
Issue number11
StatePublished - Apr 2010


  • Bone
  • Bone metastases
  • Breast cancer
  • Melanoma
  • Metastases
  • Prostatic cancer
  • TGF-β
  • TGF-β inhibitors
  • TGF-β receptors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'TGF-β pathway as a therapeutic target in bone metastases'. Together they form a unique fingerprint.

Cite this